|

Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives

RECRUITINGSponsored by University Hospital, Strasbourg, France
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2024-10-18
Est. completion2026-02
Eligibility
Age1 Month – 21 Years
View on ClinicalTrials.gov →

NCT07303140

Summary

Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.

Eligibility

Age: 1 Month – 21 Years
Inclusion Criteria:

* Minors: from birth to 17 years
* Adults: 18 to 21 years
* Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up.

Exclusion Criteria:

\- Patients monitored for type III glycogen storage disease but who had never undergone liver elastography during their follow-up.

Conditions2

Liver DiseaseLiver Fibrosis

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.